Research advances in the diagnosis and treatment of Polycystic kidney disease.
10.3760/cma.j.cn511374-20250709-00415
- Author:
Jiafa WU
1
;
Yuru JING
;
Xiaoyuan NING
Author Information
1. College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, Henan 471000, China. wujiafa@haust.edu.cn.
- Publication Type:English Abstract
- MeSH:
Humans;
Polycystic Kidney Diseases/genetics*;
TRPP Cation Channels/genetics*;
Mutation;
Polycystic Kidney, Autosomal Dominant/therapy*;
Receptors, Cell Surface
- From:
Chinese Journal of Medical Genetics
2026;43(3):234-240
- CountryChina
- Language:Chinese
-
Abstract:
Polycystic kidney disease (PKD) is a group of inherited disorders characterized by cystic lesions in the kidneys and multiple organs, primarily including autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). ADPKD is mainly caused by variations in the PKD1 and PKD2 genes. Its clinical manifestations include progressive renal cyst growth, hypertension, and multi-system complications. ARPKD, on the other hand, is primarily caused by mutations in the PKHD1 gene. It commonly occurs in infants and young children, with hepatorenal cystic fibrosis being a key feature. Although there is currently no cure for PKD, the integration of multi-omics and precision medicine strategies holds promise for optimizing patient management and improving outcomes in the future. This review summarizes the genetic basis, pathogenic mechanisms, diagnostic techniques, and therapeutic advances in PKD, providing a reference for clinical practice and research.
